Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases

Alnylam and Regeneron Pharmaceuticals are announcing a wide-ranging alliance this morning to co-develop treatments for eye and neurological diseases using RNA interference, a method of drugmaking that has recently come of age after years of ups and downs.